Wegovy Portfolio Update: Focus Shifts to Oral Pill as Injectable Sales Peak
Novo Nordisk has introduced a new oral version of its popular weight-loss drug, Wegovy. Many patients are used to the weekly injection. However, the FDA approved the daily pill in late 2025, giving patients a new option. This could be a game-changer for people who dislike injections or want a simpler routine.
Wegovy uses an active ingredient called semaglutide. This medicine mimics a natural hormone that tells the brain when the body is full. As a result, patients tend to eat less and manage blood sugar more effectively. With both pill and injection options available, doctors can choose what best fits a patient’s lifestyle.
Creating a pill form of semaglutide was challenging. Normally, stomach acid destroys peptide medicines before they can work. Scientists solved this problem using a technology called SNAC. This compound briefly changes the stomach’s acidity and protects the drug. It helps the medicine reach the bloodstream safely.
To ensure proper absorption, patients must follow a simple routine. The pill should be taken on an empty stomach with a small sip of water. Patients must then wait before eating breakfast or taking other medications.
The injectable version of Wegovy will still remain available. Many patients prefer it because it only requires one dose per week. Both the pill and injection use gradual dose increases. This helps the body adjust and reduces common stomach side effects.
The financial outlook for Wegovy is strong. Sales are expected to grow from $13.5 billion in 2026 to nearly $19 billion by 2031.
| Feature | Wegovy (Oral / Injectable) | Zepbound (Eli Lilly) |
|---|---|---|
| Mechanism | GLP-1 Agonist | Dual GLP-1 & GIP Agonist |
| Format | Daily Pill or Weekly Injection | Weekly Injection |
| Advantage | More patient choice | Potentially higher weight loss |
Like most medicines, Wegovy can cause side effects. Some patients may experience nausea or mild stomach discomfort. These effects usually improve as the body adjusts. Doctors still recommend regular monitoring to watch for rare complications.
Giving patients the option of a daily pill or weekly injection improves flexibility. It allows people to choose a treatment that fits their lifestyle. This may lead to better adherence and improved health outcomes.
The introduction of the oral version could also expand access to treatment worldwide. Some patients avoid weight-loss therapy because they feel uncomfortable with injections. A pill format may encourage more people to start treatment earlier. In addition, pharmacies and healthcare systems may find pills easier to distribute and store than injectable medicines.
Future advances in drug delivery will likely improve weight-loss treatments even further. Researchers are already exploring new formulations and combination therapies that could enhance effectiveness. As innovation continues, patients may soon benefit from more convenient and personalized obesity treatments.
